Strykagen
Private Company
Total funding raised: $5M
Overview
Strykagen is a private, preclinical-stage biotech founded in 2018, targeting significant unmet needs in rare muscular dystrophies including Duchenne (DMD), Becker (BMD), MDC1A, and Limb Girdle types. Its core technology platform centers on stabilizing the muscle extracellular matrix (myomatrix) via biologics and small molecules targeting disease modifiers. Led by a scientifically expert team, the company is building a pipeline of potential therapies and diagnostics, aiming for orphan drug designations to secure market exclusivity for its future products.
Technology Platform
Platform focused on stabilizing the muscle extracellular matrix (myomatrix) using biologics and small molecules that target disease modifiers, based on research into integrins (e.g., alpha7beta1) and laminins.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
The muscular dystrophy therapeutic space is competitive, with several approved therapies (e.g., exon-skipping drugs, glucocorticoids) and numerous companies in clinical development across gene therapy, exon skipping, and disease-modifying approaches. Strykagen's niche is its specific focus on myomatrix stabilization, a mechanism distinct from genetic correction or anti-inflammatory strategies, potentially positioning it for combination therapies or for patient subsets unresponsive to other treatments.